Pureos Bioventures, a Swiss VC investing in pre-clinical and clinical-stage drug developers, plans to raise a second fund of approximately CHF 250m-300m by the end of next year, managing partner Martin Münchbach told Unquote.
Management of the German industrial fixings supplier will reinvest with a minority stake
Management and founders will retain a 25% stake in the Spanish IT services group; bolt-ons planned under new owner
Around 40% larger than its predecessor, the new fund was raised in less than six months, managing director Johanna Barr tells Unquote
New majority owner will seek to expand the Finnish green building services specialist across Europe